JUVE Comment

The patent attorneys at Ter Meer Steinmeister are renowned for their expertise in pharmaceutical, biotechnology and chemistry patent litigation, built on many years of experience. The IP firm, with offices in Munich and Bielefeld, has recently taken on major new proceedings in the chemistry sector. The firm ranks among the most respected practices for EPO oppositions and regularly represents pharmaceutical companies. A notable instruction is the ongoing wave of EPO opposition proceedings brought by Generics UK against Novo Nordisk concerning the weight-loss drugs semaglutide/Ozempic and Wegovy.

The firm continues to expand its well-established service offering across various technical fields. The prosecution practice is developing steadily, with clients increasingly instructing the firm in the biotech sector.

In electronics, the client roster includes prominent Korean companies such as KT&G, LG Display, and LG Electronics. A key case is the recently settled proceedings for LG Display against Tianma concerning smartphone displays.

In litigation, the firm maintains long-standing relationships with several external lawyers. This has resulted in several instructions in UPC litigation within the electronics sector. However, compared with similarly focused competitors, the firm has not yet accumulated as much UPC experience. This stems partly from its core life sciences client base not yet actively engaging with the UPC. As the industry now shifts its strategy, the firm is well positioned to draw on its extensive experience representing pharmaceutical companies at the UPC.

Strengths

Litigation concerning pharmaceuticals.

Recommended individuals

Bernd Aechter (“highly experienced”, competitor), Christian Hollatz (both patent attorneys)

Team

21 patent attorneys

Clients

LG Display against Tianma over smartphone display (settled 2026); SK Displays against SFC over smartphone displays (including nullity suit); Fujifilm against Xerox over printing (including nullity suit); Nordson against STT System Industry over hot melt adhesive dosage system. EPO oppositions: Novartis against multiple generic drug companies over multiple sclerosis drug fingolimod/Gilenya (ended in 2026); Generics UK against Novo Nordisk over weight-loss drug semaglutide/Ozempic and Wegovy; Accord against Stada over bortezomib; regular opposition for Viatris and Intex Pharma (all public knowledge).